Press Release

Cipla announces Q4 FY 1213 Unaudited Financial Results

Mumbai, India, 29th May 2013: Cipla Limited (BSE: 500087, NSE : CIPLA) today announced its Unaudited Financial Results for the quarter ended March 31, 2013 (Q4).

Key Financial & Performance Highlights Q4 FY1213 vis-a-vis Q4 FY1112:

- Gross revenues grew by 4.9% to ₹1982 cr, up from ₹1890 cr in Q4 FY1112
- Operating margins grew by 2.7% to ₹409 cr, up from ₹399 cr in Q4 FY1112
- Profit after tax fell by 8.3% to ₹268 cr, down from ₹292 cr in Q4 FY1112

---

**Sales Growth**

<table>
<thead>
<tr>
<th></th>
<th>Q4 FY1112</th>
<th>Q4 FY1213</th>
</tr>
</thead>
<tbody>
<tr>
<td>India</td>
<td>754</td>
<td>793</td>
</tr>
<tr>
<td>Outside India</td>
<td>1085</td>
<td>1128</td>
</tr>
<tr>
<td>Total</td>
<td>1839</td>
<td>1921</td>
</tr>
</tbody>
</table>

**Growth in Profits**

<table>
<thead>
<tr>
<th></th>
<th>PBT</th>
<th>PAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4 FY1112</td>
<td>365</td>
<td>292</td>
</tr>
<tr>
<td>Q4 FY1213</td>
<td>372</td>
<td>268</td>
</tr>
</tbody>
</table>

**Geographical Revenue Breakup**

- India: 41%
- Outside India: 59%

**Business Mix**

- Formulations: 90%
- APIs: 10%
Profit & Loss Highlights:

- Material cost at 38.7% of Total Sales decreased by 3.3% during Q4 FY1213 as compared to Q4 FY1112.
- Operating margins increased by 2.7% and is at 20.7% of Income from Operations during Q4 FY1213.
- Profit after tax decreased by 8.3% to ₹268 cr during Q4 FY1213 as compared to ₹292 cr during Q4 FY1112.

Performance Review:

Domestic business:

- Domestic revenues grew by 5.2% to ₹793 cr during Q4 FY1213, up from ₹754 cr during Q4 FY1112.
- The growth in domestic revenues was largely on account of growth in anti-asthma, anti-biotics/infectives, and cardiovascular therapy segments.

International business:

- Exports of formulations grew by 11.5% to ₹954 cr during Q4 FY1213, up from ₹855 cr during Q4 FY1112.
- Exports of APIs fell by 24.0% to ₹175 cr during Q4 FY1213, from ₹230 cr during Q4 FY1112.
- The growth in export revenues was primarily due to growth in anti-asthma, anti-allergic, anti-depressants, and anti-retroviral segments.

About Cipla:
Cipla laid foundations for the Indian pharmaceutical industry back in 1935 with the vision to make India self-reliant in healthcare. Over the years Cipla has emerged as one of the most respected names not just in India but worldwide. Its state of the art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. With over 34 manufacturing units across the country, Cipla manufactures over 2000 products in 65 therapies.

With a turnover of over US$ 1.4 billion, Cipla serves doctors and patients in over 170 countries. It has earned a name for maintaining one global standard across all its products and services. Cipla continues to support, improve and save millions of lives with its high-quality drugs and innovative devices. (www.cipla.com).

Media Contact:

Finance
Ajay Luharuka
Contact No.: 022 – 23025435
E-Mail: ajay@cipla.com

Corporate Communications
Jaisingh Balakrishnan
Contact No.: 022 - 23025813
E Mail: jaisingh.krishnan@cipla.com